Calamos Advisors LLC Sells 8,584 Shares of Novo Nordisk A/S (NYSE:NVO)

Calamos Advisors LLC trimmed its position in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 2.6% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 323,754 shares of the company's stock after selling 8,584 shares during the quarter. Calamos Advisors LLC's holdings in Novo Nordisk A/S were worth $33,492,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also recently bought and sold shares of the company. Jennison Associates LLC boosted its holdings in shares of Novo Nordisk A/S by 100.3% in the 3rd quarter. Jennison Associates LLC now owns 23,419,405 shares of the company's stock worth $2,129,761,000 after buying an additional 11,727,507 shares during the last quarter. Polen Capital Management LLC bought a new stake in Novo Nordisk A/S in the 3rd quarter valued at about $718,995,000. FMR LLC raised its stake in Novo Nordisk A/S by 122.7% in the 3rd quarter. FMR LLC now owns 12,077,501 shares of the company's stock valued at $1,098,328,000 after acquiring an additional 6,654,614 shares during the period. Morgan Stanley raised its stake in Novo Nordisk A/S by 96.5% in the 3rd quarter. Morgan Stanley now owns 9,215,098 shares of the company's stock valued at $838,021,000 after acquiring an additional 4,526,199 shares during the period. Finally, Loomis Sayles & Co. L P raised its stake in Novo Nordisk A/S by 91.7% in the 3rd quarter. Loomis Sayles & Co. L P now owns 9,097,808 shares of the company's stock valued at $827,354,000 after acquiring an additional 4,350,862 shares during the period. 11.54% of the stock is owned by hedge funds and other institutional investors.

Novo Nordisk A/S Price Performance

Shares of NVO traded down $1.77 during midday trading on Thursday, hitting $122.76. 2,840,069 shares of the company traded hands, compared to its average volume of 4,881,376. The company has a debt-to-equity ratio of 0.19, a current ratio of 0.82 and a quick ratio of 0.64. The stock has a 50-day moving average of $126.36 and a 200-day moving average of $110.50. The firm has a market cap of $550.89 billion, a P/E ratio of 45.38, a PEG ratio of 2.06 and a beta of 0.41. Novo Nordisk A/S has a one year low of $75.56 and a one year high of $138.28.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last posted its quarterly earnings data on Wednesday, January 31st. The company reported $0.71 earnings per share for the quarter, topping the consensus estimate of $0.66 by $0.05. The company had revenue of $9.51 billion for the quarter, compared to analysts' expectations of $9.14 billion. Novo Nordisk A/S had a net margin of 36.03% and a return on equity of 90.36%. As a group, sell-side analysts predict that Novo Nordisk A/S will post 3.33 EPS for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The business also recently disclosed a Semi-Annual dividend, which was paid on Tuesday, April 2nd. Investors of record on Monday, March 25th were given a $0.664 dividend. This represents a dividend yield of 0.9%. This is a boost from Novo Nordisk A/S's previous Semi-Annual dividend of $0.22. The ex-dividend date was Friday, March 22nd. Novo Nordisk A/S's dividend payout ratio is 49.17%.

Analyst Upgrades and Downgrades

NVO has been the topic of a number of research reports. UBS Group initiated coverage on Novo Nordisk A/S in a research note on Tuesday, January 16th. They issued a "neutral" rating on the stock. Morgan Stanley initiated coverage on Novo Nordisk A/S in a research note on Tuesday, January 23rd. They issued an "overweight" rating and a $120.00 price objective on the stock. Cantor Fitzgerald restated an "overweight" rating and issued a $160.00 price objective on shares of Novo Nordisk A/S in a research note on Thursday. Finally, BMO Capital Markets initiated coverage on Novo Nordisk A/S in a research note on Friday, April 12th. They issued an "outperform" rating and a $163.00 price objective on the stock. Two equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $133.60.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.